The Insulin That Kids Don't Have to Fear

But MannKind's investigators traced the miss to a single patient who wasn't following the protocol. Remove that outlier, and the gap drops to 0.370%, comfortably within the margin. The modified analysis met the primary endpoint.

Now, if you're a skeptic, you might raise an eyebrow at removing a patient to make the numbers work. That's fair. The FDA will almost certainly scrutinize that decision closely. But modified intent-to-treat analyses aren't unusual in clinical trials; they're a standard tool when protocol violations clearly skew results. The question is whether the agency buys the explanation.

The Lung Question Nobody Can Ignore

Afrezza isn't just insulin in a different package. It delivers medication directly to the lungs, and that comes with baggage.

The adult version carries a black box warning (the FDA's most serious label alert) for the risk of acute bronchospasm, the sudden tightening of airways. It's completely off-limits for anyone with asthma or COPD. Even in healthy adults, Afrezza causes a small but measurable decline in lung function: about 40 milliliters of FEV1 (a standard measure of how much air you can forcefully exhale) over two years. Roughly 6% of adult Afrezza users saw their FEV1 drop by 15% or more, compared to 3% of patients on other diabetes treatments.

For adults with fully developed lungs, that's a manageable tradeoff. But children's lungs are still growing. Asking the FDA to approve a drug that touches developing airways is a different conversation entirely.

The INHALE-1 data was reassuring on this front: MannKind reported no clinically meaningful differences in lung function between the Afrezza and injection groups over 26 weeks. No new or unexpected safety signals popped up compared to the adult profile, and hypoglycemia rates were similar between groups.

Still, 26 weeks (even with 52 weeks of total safety data from the extension phase) is a blink of an eye when you're talking about a child who might use this product for decades. Expect the FDA to think long and hard about post-marketing requirements if it gives the green light.

Why This Matters More Than You Think

The numbers on pediatric type 1 diabetes are moving in the wrong direction. Incidence in Americans under 20 climbed from 19.5 per 100,000 in 2002 to 22.2 per 100,000 by 2018, a steady rise of about 2% per year. The CDC projects that T1D in young people could increase by roughly 65% by 2060.

Every one of those kids faces the same daily gauntlet: multiple needle sticks, carb counting, dose calculations, school-nurse logistics, and the ever-present fear of getting it wrong. Needle phobia (clinically called trypanophobia) isn't just a childhood quirk; it's a real barrier that causes kids to skip or under-dose insulin, especially in social settings. Skipped doses lead to higher HbA1c, which leads to more hospitalizations, which leads to worse long-term outcomes.

Right now, families who want to reduce the needle burden have one main option: insulin pumps. Devices like the Omnipod 5 or Tandem's Control-IQ replace daily injections with a small cannula inserted every few days. They're excellent technology, but they're expensive, require training, and still involve needles (just fewer of them). Not every family has access, and not every kid wants a device attached to their body.

Afrezza would offer something genuinely different: a mealtime insulin that a kid takes by breathing. No insertion site, no tubing, no adhesive patch. Think of it as the difference between swallowing a pill and getting a shot. Both deliver medicine, but one of them doesn't make a six-year-old cry.

The catch? Even with Afrezza, kids would still need a daily basal insulin injection. It's a needle-reduction strategy, not needle elimination. But going from four or five shots a day down to one is a meaningful quality-of-life upgrade for a child.

The Business Side: Small Revenue, Big Signal

Let's be honest about the commercial picture. Afrezza is not a blockbuster. It pulled in $74.6 million in net sales for 2025, up 16% from the prior year. That Q4 number of $22.9 million (up 25% year over year) shows accelerating momentum, but this is still a niche product in a market dominated by injectable insulin giants like Novo Nordisk and Eli Lilly.

Wall Street isn't expecting a pediatric approval to change that overnight. Most analyst models pencil in low-to-mid single-digit millions in extra revenue during the first 12 to 18 months of a pediatric launch. Pediatric endocrinologists will need education, payers will need convincing, and parents will need real-world reassurance.

The bigger significance is strategic. Proving that Afrezza works safely in developing lungs validates MannKind's entire Technosphere platform for a new generation of patients. It also opens the door to longer-term growth: some bullish scenarios see Afrezza eventually reaching the low hundreds of millions in annual sales if both adult and pediatric adoption expand together.

Analysts generally view approval as more likely than not, with implied probabilities hovering around 60 to 80%. The main risk factor is straightforward: if the FDA wants more long-term pulmonary data in children, MannKind could receive a complete response letter (a polite "not yet") instead of an approval.

Six Days and Counting

The PDUFA date is May 29, 2026. That's the deadline for the FDA to act: approve, reject, or ask for more information.

If it's a yes, a four-year-old with type 1 diabetes will, for the first time ever, have access to an FDA-approved mealtime insulin that doesn't involve a needle. That sentence has never been true before in the history of pediatric diabetes care.

If it's a no (or a "not yet"), MannKind will likely need additional long-term safety studies, pushing any pediatric launch by years. The window for these kids doesn't close forever, but it stays shut a lot longer.

Either way, the fact that we're even having this conversation reflects something important. For decades, the only innovation in pediatric insulin delivery was making needles thinner and pumps smarter. Asking whether a child can simply inhale their mealtime insulin is a fundamentally different question, and on Thursday, we'll find out if the FDA thinks the answer is ready.

Big Pharma's Quiet Purge Keeps Rolling Through Summer

AbbVie and Novartis both filed U.S. layoff notices in the same week, continuing a restructuring wave sweeping big pharma. The cuts aren't signs of weakness; they're signs of a much bigger transformation underway.